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Systemic primary carnitine deficiency (CDSP) is an autosomal recessive disorder of carnitine transportation. The
clinical manifestations of CDSP can vary widely with respect to age of onset, organ involvement, and severity of
symptoms, but are typically characterized by episodes of hypoketotic hypoglycemia, hepatomegaly, elevated
transaminases, and hyperammonemia in infants; skeletal myopathy, elevated creatine kinase (CK), and
cardiomyopathy in childhood; or cardiomyopathy, arrhythmias, or fatigability in adulthood. The diagnosis can be
suspected on newborn screening, but is established by demonstration of low plasma free carnitine concentration
(<5 μM, normal 25-50 μM), reduced fibroblast carnitine transport (<10% of controls), and molecular testing of the
SLC22A5 gene. The incidence of CDSP varies depending on ethnicity; however the frequency in the United States is
estimated to be approximately 1 in 50,000 individuals based on newborn screening data. CDSP is caused by
recessive mutations in the SLC22A5 gene. This gene encodes organic cation transporter type 2 (OCTN2) which
transport carnitine across cell membranes. Over 100 mutations have been reported in this gene with the c.136C > T
(p.P46S) mutation being the most frequent mutation identified. CDSP should be differentiated from secondary
causes of carnitine deficiency such as various organic acidemias and fatty acid oxidation defects. CDSP is an
autosomal recessive condition; therefore the recurrence risk in each pregnancy is 25%. Carrier screening for at-risk
individuals and family members should be obtained by performing targeted mutation analysis of the SLC22A5 gene
since plasma carnitine analysis is not a sufficient methodology for determining carrier status. Antenatal diagnosis for
pregnancies at increased risk of CDSP is possible by molecular genetic testing of extracted DNA from chorionic
villus sampling or amniocentesis if both mutations in SLC22A5 gene are known. Once the diagnosis of CDSP is
established in an individual, an echocardiogram, electrocardiogram, CK concentration, liver transaminanses
measurement, and pre-prandial blood sugar levels, should be performed for baseline assessment. Primary treatment
involves supplementation of oral levocarnitine (L-carnitine) at a dose of 50–400 mg/kg/day divided into three
doses. No formal surveillance guidelines for individuals with CDSP have been established to date, however the
following screening recommendations are suggested: annual echocardiogram and electrocardiogram, frequent
plasma carnitine levels, and CK and liver transaminases measurement can be considered during acute illness. Adult
women with CDSP who are planning to or are pregnant should meet with a metabolic or genetic specialist ideally
before conception to discuss management of carnitine levels during pregnancy since carnitine levels are typically
lower during pregnancy. The prognosis for individuals with CDSP depends on the age, presentation, and severity of
symptoms at the time of diagnosis; however the long-term prognosis is favorable as long as individuals remain on
carnitine supplementation.* Correspondence: elhattabaw@yahoo.com
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Systemic primary carnitine deficiency
Carnitine deficiency
Systemic primary (CDSP)
Carnitine uptake deficiency (CUD)
Systemic carnitine deficiency (SCD)
Primary carnitine deficiency
Deficiency of plasma-membrane carnitine transporter
Definition and diagnostic criteria
Systemic primary carnitine deficiency (CDSP) is an auto-
somal recessive disorder of carnitine transportation typic-
ally characterized by episodes of hypoketotic hypoglycemia,
hepatomegaly, elevated transaminases, and hyperammone-
mia in infants; skeletal myopathy, elevated creatine kinase
(CK), and cardiomyopathy in childhood; or fatigability in
adulthood [1]. There is a considerably broad phenotypic
range associated with this condition, ranging from early
infantile decompensation to adults who are asymptomatic,
therefore, establishing the diagnosis early is essential to
guide management. The diagnosis can be suspected on
newborn screening, but is established by demonstration of
low plasma free carnitine concentration (<5 μM, normal
25-50 μM), reduced fibroblast carnitine transport (<10% of
controls), and molecular testing of the SLC22A5 gene [2].
Epidemiology
The incidence of CDSP varies depending on ethnicity. In
Japan, the incidence of CDSP is approximately 1 in 40,000
[3], whereas the frequency in Australia is approximately 1
in 120,000 [4]. The frequency in the United States and
Europe has not been established, however is estimated to
occur in approximately 1 in 20,000 - 70,000 individuals
based on newborn screening data from various states in-
cluding Missouri, Texas, and California [personal commu-
nication]. Since some individuals with CDSP may remain
asymptomatic throughout their entire life, the prevalence
of CDSP in the general population may be much higher
than originally anticipated since this particular cohort may
be underascertained and undiagnosed.
CDSP is an autosomal recessive condition; therefore,
we would expect the disorder to occur with equal fre-
quency in males and females. However, apparent sex
ratio may be skewed because more adult women may be
diagnosed secondary to their infants being diagnosed
with CDSP and more adult women than men may actu-
ally experience symptoms related to CDSP, particularly
during pregnancy which can exacerbate symptoms.
Clinical description
The clinical manifestations of CDSP can vary widely with
respect to age of onset, organ involvement, and severity of
symptoms. The most common presentations are in infancy
and early childhood with either metabolic decompensationor cardiac and myopathic manifestations, respectively.
Adults with CDSP have been reported with mild or no
symptoms.
Infantile metabolic (hepatic) presentation
Approximately half of the reported patients present
around the age of 2 years old (range: 3 months –
2.5 years) with metabolic decompensation characterized
by episodes of hypoketotic hypoglycemia, hyperammo-
nemia, hepatomegaly, elevated transaminases, and hep-
atic encephalopathy (poor feeding, irritability, lethargy).
These episodes may be triggered by fasting or common
illnesses such as upper respiratory tract infections. Car-
diomyopathy, skeletal muscle weakness, and mildly ele-
vated creatine kinase (CK) values may be seen in older
children with this presentation. Without treatment with
intravenous dextrose infusions during these episodes,
children may fall into a coma and die [5].
Childhood myopathic (cardiac) presentation
The remaining half of patients typically present in later
childhood around the age of 4 years (range: 1 year to
7 years) with dilated cardiomyopathy, hypotonia, muscle
weakness, and elevated CK. Cardiomyopathy in individuals
with CDSP can be progressive and may result in death
before a diagnosis is established or treatment initiated.
Adulthood presentation
Adults with CDSP have been reported with no symptoms
or mild symptoms including decreased stamina or easy
fatigability [1,6–9]. Some women with CDSP have been
ascertained after newborn screening identified low carni-
tine levels in their infants. Carnitine is transferred from
the placenta to the fetus during the prenatal period.
Therefore, shortly after birth, carnitine levels in newborns
reflect those of the mother [10,11]. Expanded newborn
screening via tandem mass spectroscopy subsequently
detects the low carnitine level in the newborn providing a
false-positive result of CDSP for the child. This result
should prompt the clinician to probe further into the ma-
ternal history and to obtain carnitine levels on the mother
since it may be an indication of underlying CDSP in the
mother. In studies of women who were ascertained in this
way, approximately half were asymptomatic whereas the
other half indicated a history of decreased stamina or easy
fatigability [1,7–9]. Symptoms, such as decreased stamina
or worsening cardiac arrhythmia, may become unmasked
during pregnancy [1,8]. This could be due to the increased
energy consumption and metabolically challenging state of
pregnancy, as well as the normal physiologic decreases in
plasma carnitine levels that can occur in any pregnancy
[12]. Cardiac findings such as dilated cardiomyopathy and
arrhythmias have also been reported in a few adult
patients with CDSP [7].
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individuals with CDSP include anemia [13], proximal
muscle weakness and developmental delay [14], respira-
tory distress [15], and arrhythmias and electrocardio-
gram abnormalities [8,16].
Etiology
Carnitine (3-hydroxy-4-trimethylaminobuyric acid) is
mostly derived from dietary intake, but can also be synthe-
sized from lysine and methionine in the liver and kidney.
Carnitine is required for the transfer of long-chain fatty
acids from the cytoplasm into the mitochondria for beta
oxidation [5]. During periods of fasting, fatty acids are the
predominant source of energy production. Thus, if carni-
tine is deficient, this will result in defective fatty acid oxi-
dation. When fat cannot be utilized glucose is consumed
without regeneration via gluconeogenesis resulting in
hypoglycemia. In addition, fat released from adipose tissue
accumulate in the liver, skeletal muscle, and heart resulting
in hepatic steatosis and myopathy [2].
CDSP is caused by recessive mutations in the
SLC22A5 gene. This gene encodes organic cation trans-
porter type 2 (OCTN2), which is part of a larger family
of OCTNs that play a significant role in transporting or-
ganic cation compounds across cell membranes. OCTN2
transfers carnitine across the cell membrane in a
sodium-dependent manner. When OCTN2 is not work-
ing properly, this can result in improper transfer of car-
nitine across the cell membrane resulting in a) urinary
carnitine wasting leading to low plasma carnitine levels,
and b) decreased intracellular carnitine accumulation.
The SLC22A5 gene is located on chromosome 5q23.3
and is comprised of 10 exons spanning approximately 3.2
kilobases (kb). The gene product, OCTN2, is a transmem-
brane protein composed of 557 amino acids that includes
12 transmembrane domains and one ATP binding do-
main. Over 100 mutations have been reported in this gene
in the Human Gene Mutation Database (http://www.
hgmd.cf.ac.uk/ac/index.php) and the SLC22A5 database at
the ARUP Laboratories (http://www.arup.utah.edu/data-
base/OCTN2/OCTN2_display.php). Approximately half
of these mutations are missense, while the other half are
composed of nonsense, splice site, and deletion/insertion
mutations. These mutations result in dysfunctional
OCTN2 gene product and decreased carnitine transport
in various tissues. Li et al. sequenced the SLC22A5 gene in
70 infants with low carnitine levels detected by newborn
screening and identified two mutations in 23 infants and
one mutation in 25 infants for a detection rate in this
population of nearly 70%. The most frequently occurring
mutation in this cohort was the c.136C>T (p.P46S) muta-
tion which was identified in about 15% of the mutant
alleles [9]. The p.P46S mutation was initially reported in
mothers with primary carnitine deficiency identified byexpanded newborn screening in the child [8]. Subsequent
studies found that the p.P46S mutation is most frequently
encountered in asymptomatic or minimally symptomatic
adults. The presumption that this mutation may be asso-
ciated with a milder phenotype was further suggested by
studies that demonstrated that the OCTN2 protein prod-
uct with this mutation retains some residual carnitine
transport activity [17].
Diagnostic methods
Plasma free carnitine concentration
Measurement of plasma carnitine levels of individuals
with CDSP will show extremely reduced plasma free car-
nitine levels (<5 μM, normal 25-50 μM) [1]. Urine carni-
tine excretion in individuals with CDSP who are on
carnitine supplementation is typically very high. The
diagnosis of CDSP may first be suspected when low
plasma carnitine concentration is identified via newborn
screening using tandem mass spectrometry (i.e. low
levels of free carnitine (C0)) [18]. However, since carni-
tine is transferred across the placenta to the fetus during
intrauterine life, shortly after birth, the infants’ carnitine
level may actually be a reflection of their mothers’ carni-
tine levels [10]. This may lead to a false positive diagno-
sis of CDSP in the infant, but a true positive diagnosis of
CDSP in the mother. Carnitine levels in unaffected new-
borns should normalize within two weeks after birth,
therefore, if the initial newborn screen is suggestive of
carnitine deficiency, a repeat plasma carnitine analysis
should be performed. If the carnitine levels normalize
without carnitine supplementation, then there is no add-
itional need to screen the infant for carnitine deficiency.
Molecular
Further confirmation of the diagnosis, however, relies on
molecular genetic testing of the SLC22A5 gene. Se-
quence analysis is clinically available and can detect at
least one mutation in approximately 70% of affected
individuals. Large deletions and duplications of the
SLC22A5 gene, while not a common mechanism of
causing CDSP, have been identified in at least one indi-
vidual with this diagnosis [9]. Therefore, if sequence
analysis is negative, or only detects one mutation in an
individual strongly suspected of having CDSP, then array
comparative genomic hybridization (aCGH) is recom-
mended to screen for larger deletions and duplications
that may involve part of or the entire SLC22A5 gene.
Fibroblast carnitine transport
If molecular and aCGH fail to detect mutations or large
deletions of the gene, then a skin biopsy may be considered
to assess carnitine transport in cultured fibroblasts. Carni-
tine transport in skin fibroblast from individuals with CDSP
is typically reduced below 10% of control rates [2,19].
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CDSP should be differentiated from secondary causes of
carnitine deficiency. Several groups of inherited metabolic
disorders can cause carnitine deficiency, including, organic
acidemias and fatty acid oxidation defects such as very
long chain acyl-CoA dehydrogenase (VLCAD), medium-
chain acyl-CoA dehydrogense (MCAD), long-chain hydro-
xyacyl-CoA dehydrogenase (LCHAD), and carnitine pal-
mitoyltransferase II (CPT II) deficiencies. CDSP can be
differentiated from other fatty acid oxidation defects by
demonstration of very low free carnitine levels in plasma
(C0) with normal acylcarnitine profile (the concentration
of different length acylcarnitine species).
Pharmacological therapy, such as cyclosporine, pivam-
picillin, and valproate, malnutrition, renal tubular dysfunc-
tion, prematurity, and prolonged TPN (total parenteral
nutrition) feedings without carnitine supplementation
may also cause secondary carnitine deficiency. CDSP can
be differentiated from these conditions by careful review
of the patient’s medical history, medication history, and
biochemical laboratory test results. If plasma carnitine
levels are extremely low, and if carnitine levels do not
respond to removing the offending agent, then one could
pursue further diagnostic testing by sequencing of the
SLC22A5 gene and/or fibroblast carnitine transport assay.
Genetic counseling
CDSP is inherited in an autosomal recessive manner.
Therefore, parents of an individual with CDSP are obligate
heterozygous carriers. Heterozygous carriers are asymp-
tomatic. Kozumi et al. reported that left ventricular hyper-
trophy, described as marginal, late-onset, and benign, was
observed in heterozygous mutation carriers of SLC22A5
[3]. A more recent study however screened a cohort of
individuals with cardiomyopathy for mutations in SLC22A5
and did not see an increased prevalence of heterozygous
mutations in this population, concluding that heterozygos-
ity for SLC22A5 is unlikely to result in a significant risk for
cardiomyopathy in adulthood [20]. Heterozygous carriers
usually have approximately 50% carnitine transport activity
in fibroblasts and may have normal or borderline low car-
nitine levels in plasma [21]. Therefore, plasma carnitine
analysis alone is not sufficient to determine an individual’s
carrier status since carnitine levels may be in the normal
range. Molecular genetic testing for determining carrier
status is considered the preferred method for determining
an individual’s carrier status [1].
Since CDSP is an autosomal recessive condition, the
recurrence risk in each pregnancy is 25%. Siblings of
individuals known to be affected with CDSP should have
plasma carnitine analysis to determine if they are also
affected with CDSP. However, as mentioned previously,
this test is not a reliable method for determining carrier
status. In addition, mothers of infants who have anabnormal newborn screen suggestive of carnitine defi-
ciency should have plasma carnitine analysis as well
since it may reveal that the mother, rather than the in-
fant, is affected with CDSP since the infant’s carnitine
level may be a reflection of the mother’s carnitine level.
Repeating the infant’s carnitine level can determine if
the infant’s initial low carnitine was a false positive.
Other family members have an increased risk of being a
carrier for CDSP. If carrier status needs to be determined,
molecular genetic testing is the preferred method and is
clinically available. Once the mutations in the family are
identified, target mutation analysis can be offered to any
at-risk individual or family member interested in deter-
mining their carrier status. If one or no mutations are
identified in the affected proband, then fibroblast carnitine
transport analysis may be offered to screen for carriers
since heterozygous carriers have approximately 50% carni-
tine transport activity when compared to non-carriers.
Genotype-phenotype correlations suggest that non-
sense and frameshift mutations are more likely to be
associated with lower carnitine transport and are more
prevalent in symptomatic individuals whereas missense
mutations and inframe deletions many result in residual
carnitine transport activity and are more common in
asymptomatic individuals [22].
Antenatal diagnosis
Antenatal diagnosis is possible by molecular genetic test-
ing of extracted DNA from chorionic villus sampling or
amniocentesis. However, the identification of both muta-
tions in the SLC22A5 gene is required in order to be
able to offer prenatal diagnosis for this condition. Pre-
natal diagnosis can also be performed by measuring car-
nitine transport in amniocytes obtained from amniotic
fluid [11]. Antenatal diagnosis for CDSP has seldom
been performed since this condition is treatable and car-
nitine supplementation may be initiated at birth while
the diagnostic testing is pending.
Management
Individuals with the suspected or confirmed diagnosis of
CDSP should be referred to a metabolic or genetic spe-
cialist so that appropriate management, anticipatory
guidance, and genetic counseling can be initiated as
soon as possible. Once the diagnosis of CDSP is estab-
lished in an individual, the following evaluations should
be performed for baseline assessment:
 Echocardiogram to screen for cardiomyoapthy
 Electrocardiogram to screen for arrhythmias
 Creatine kinase (CK) concentration to assess muscle
involvement
 Liver transaminases to assess liver function
 Pre-prandial blood sugar to assess hypoglycemia
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be prevented by maintaining normal plasma carnitine levels.
Primary treatment involves supplementation of oral levocar-
nitine (L-carnitine) at a dose of 50–400 mg/kg/day divided
into three doses [2]. The exact dose of carnitine supple-
mentation should be adjusted accordingly based on the
individual’s plasma carnitine level. While L-carnitine supple-
mentation has relatively few side effects, high doses may re-
sult in increased gastrointestinal motility, diarrhea, intestinal
discomfort, and/or the production of trimethylamine, which
can result in a fishy odor [19]. Decreasing the carnitine
dose may reduce this potential side-effect. If that does not
improve the odor, then a course of oral metronidazole at a
dose of 10 mg/kg/day for 7–10 days may be indicated.
Maintaining plasma carnitine levels will also reduce
the risk of hypoglycemic episodes. Other ways to prevent
hypoglycemic episodes in individuals with CDSP would
include frequent feeding and avoiding fasting. If an indi-
vidual with CDSP is hospitalized for hypoglycemia, or
needs to fast because of a medical or surgical procedure,
treatment with intravenous dextrose is recommended.
To date, there have been no formal surveillance guide-
lines for individuals with CDSP; however the following
screening recommendations are suggested based on the
author’s experience (see Table 1):
 Echocardiogram and electrocardiogram annually
during childhood and less frequently in adulthood.
Individuals with cardiomyopathy should be referred to
cardiology for further management and treatment.
 Plasma carnitine levels should be obtained and
monitored frequently (after two weeks of each dose
adjustment) until levels reach within the normal
range. Once normalization is reached, periodic
plasma carnitine analysis should be obtained twice a
year in childhood and annually for adults.
 CK and liver transaminases measurement can be
considered during acute illness.
Adult women with CDSP who are planning to or are
pregnant should meet with a metabolic or genetic specialistTable 1 Recommended clinical evaluations and management







Creatine kinase (CK) Assess muscle involvement At
Liver transaminases Assess liver function At
Pre-prandial blood sugar Assess hypoglycemia At




Initiate referrals to genetic
or metabolic specialist
Confirmation of diagnosis,
molecular genetic testing, genetic
counseling, treatment
At
freideally before conception to discuss management of carni-
tine levels during pregnancy. Pregnancy is a metabolically
challenging state since energy consumption increases signifi-
cantly during this period. In addition, women without CDSP
typically have lower plasma carnitine levels during preg-
nancy [12]. Consequences of low plasma carnitine levels in
women with CDSP may manifest as increased fatigability or
worsening cardiac arrhythmia [1,8]. Therefore, plasma carni-
tine levels should be closely monitored during pregnancy
recognizing that the dose may need to be increased during
the pregnancy. Carnitine crosses the placenta during preg-
nancy and is metabolized to some extent by the placenta
[23]; however animal studies and the limited studies on
humans have not demonstrated any teratogenic effects on
the developing fetus in cases where the mother was supple-
mented with carnitine at standard doses [24].
Prognosis
The prognosis for individuals with CDSP depends on
the age, presentation, and severity of symptoms at the
time of diagnosis. The infantile metabolic and childhood
myopathic presentations of CDSP can be fatal if not
treated early. Treatment with L-carnitine supplementa-
tion should be initiated as soon as possible before irre-
versible organ damage occurs. In addition, metabolic
decompensation and skeletal and cardiac muscle func-
tions improve after carnitine supplementation. The long-
term prognosis is favorable as long as individuals remain
on carnitine supplementation. Recurrent hypoglycemic
attacks and sudden death from cardiac arrhythmia have
been reported in several individuals who discontinued
carnitine supplementation [2,5,19,25]. These outcomes
may have potentially been avoided with proper compli-
ance of carnitine supplementation by the individual and
directive and formidable counseling regarding the
importance, efficacy, and necessity of prolonged carni-
tine supplementation by the healthcare provider.
Unresolved questions
There are reports of individuals with the confirmed diag-
nosis of CDSP being asymptomatic. The limited literaturefor individuals with systemic primary carnitine deficiency
eening and surveillance
time of diagnosis, then annually during childhood; less frequent in adulthood;
rral to cardiology if cardiomyopathy or arrhythmia are noted.
time of diagnosis, then consider measurement during acute illness
time of diagnosis, then consider measurement during acute illness
time of diagnosis, then as needed
tained and monitored frequently until levels reach within normal range.
en obtain twice a year in childhood; annually in adulthood.
time of diagnosis, then twice a year in childhood, annually in adulthood,
quently during pregnancy
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health risks make it unclear if treatment in this population
is indicated or warranted. However, based on experience
with other fatty acid oxidation defects such as medium-
chain acyl CoA dehydrogenase (MCAD) deficiency, where
individuals can be asymptomatic throughout their life
until they have an acute episode during times of stress or
illness, and then die suddenly, it has been suggested that
carnitine supplementation in asymptomatic individuals
with CDSP should be initiated [1]. Diet provides approxi-
mately 75% of daily carnitine requirement. This may play
a role in modulating the variability and severity of features
in individuals with CDSP, especially in those who remain
asymptomatic throughout their lifetime.
Ascertainment of individuals with CDSP was initially
based on the more severe symptomatic cases. However,
with the advent of expanded newborn screening, more
infants (and adults) with milder or asymptomatic pre-
sentations are getting the diagnosis. Therefore the actual
prevalence of this condition in the general population
may be much higher than originally anticipated.
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